School of Medicine
Showing 71-80 of 95 Results
-
Klaus Porzig
Emeritus Adjunct Clinical Professor, Medicine - Oncology
BioKlaus Porzig is an Emeritus Adjunct Clinical Professor at Stanford. He was active in Stanford’s clinical oncology program from 1979 until 2008. He was an Attending Physician on the Oncology inpatient service (MED III initially and then MED X) annually from 1979 until retirement in 2008. He was active in the breast cancer program during those decades. Dr. Porzig was a founding partner in South Bay Oncology in 1979 which became part of the Stanford Cancer Center in the Southbay after his retirement. He was a member of the council of the California Breast Cancer Research Program from 2006-2010 and served as the Chair of the CBCRP council 2008-2009. From 2013 to 2021, he was a member of the Stanford Medicine Alumni Association Board of Governors and served as chair of the Awards Committee during that time. Klaus has been a docent at Stanford's Jasper Ridge Biological Preserve since 2018.
PROFESSIONAL EDUCATION
B.A., Stanford University, Biology “With Great Distinction” and “Departmental Honors” (1969)
M.D., Stanford University School of Medicine (1973)
POSTGRADUATE TRAINING
Internship: Internal Medicine, University of California, San Francisco (1973-74)
Residency: Internal Medicine, Stanford (1974-75)
Research Fellowship: Laboratory of Cellular and Molecular Biology, National Cancer Institute, NIH (1976-78)
Clinical Fellowship: Medical Oncology, Stanford University (1975-76, 1978-79)
ACADEMIC HONORS AND AWARDS
Phi Beta Kappa (1968)
Alpha Omega Alpha (1972)
Winslow J. Cutting Book Award for research in Pharmacology, Stanford (1973)
Russel V. Lee Clinical Teaching Award for Excellence in Clinical Teaching, Medicine, Stanford (1994,1997,1999, and 2000)
Thomas E. Davis Award for Clinical Teaching, Oncology, Stanford (1995)
Honorary Lifetime Medical Staff, Stanford University Hospital (2013) -
Kavitha Ramchandran
Clinical Professor, Medicine - Oncology
Current Research and Scholarly InterestsMy research focuses on innovative models of care delivey to understand how to integrate primary and specialist palliative care. We also do work in palliative care education and how to scale our education to be impactful and sustainable. We are evaluating online models.
In cancer care I do research on novel therapeutics in thoracic malignancies including immunotherapy, new targeted agents, and new sequencing of approved drugs. -
Julia D. Ransohoff
Instructor, Medicine - Oncology
BioDr. Ransohoff received her B.A. from Harvard College in Human Developmental and Regenerative Biology and completed her medical training at Stanford University, where she received her M.D., completed residency in internal medicine, and fellowship training in hematology and oncology as part of the American Board of Internal Medicine Physician Scientist Training Program.
Dr. Ransohoff is a physician-scientist dedicated to improving breast cancer treatments and outcomes through developing genomic methods to profile how tumors respond to treatment. Her research focuses on molecular approaches to understand the variable clinical responses of breast cancers to treatment at the genomic level by profiling molecular residual disease. Her current work involves exploring mechanisms of chemoresistance and immune evasion and identifying novel therapeutic targets. In related work, she also studies epidemiological risk factors for breast cancer mortality with a focus on the gut microbiome, oncofertility, and racial and ethnic differences in treatment response. Dr. Ransohoff's research has been supported by the ASCO Conquer Cancer Foundation, the Terri Brodeur Breast Cancer Foundation, the Stanford Cancer Institute, ECOG-ACRIN, and the Chan Zuckerberg Initiative.
As an Instructor in the Division of Medical Oncology, Dr. Ransohoff is also a clinically active oncologist, treating patients with breast cancer. -
Fauzia Riaz, MD, MHS
Assistant Professor of Medicine (Oncology)
BioDr. Riaz is advancing biomarker-driven precision medicine in breast cancer through innovative clinical trials that integrate cutting-edge therapeutics and molecular insights.
Her research focuses on circulating tumor DNA (ctDNA) to detect minimal residual disease (MRD) in early-stage breast cancer, aiming to guide personalized treatment strategies. She is also developing novel approaches to enhance immunotherapy efficacy by modulating the tumor microenvironment, including early-phase trials that combine immunotherapy with radiotherapy. As an Assistant Professor at Stanford University School of Medicine, Dr. Riaz is committed to ensuring that these next-generation therapies are accessible to all patients.. -
Rajat Rohatgi
Professor of Biochemistry and of Medicine (Oncology)
Current Research and Scholarly Intereststhe overall goal of my laboratory is to uncover new regulatory mechanisms in signaling systems, to understand how these mechanisms are damaged in disease states, and to devise new strategies to repair their function.
-
Mohana Roy, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Roy is a medical oncologist and a clinical assistant professor in the Stanford University School of Medicine Department of Medicine, Division of Medical Oncology. She has expertise in Lung and Thoracic cancers, but with a broad clinical interest in oncology, including in Carcinoma of Unknown Primary (CUP).
Dr. Roy became an oncologist because of her passion for patient care. She is committed to being a clinician and is focused on improving the patient experience, given how the complex process of getting cancer care can be made a bit more seamless. She is the Associate Medical Director for Quality at Stanford Cancer Center from 2022.
She had led major efforts in the cancer program including starting standardized discharge follow up for patients after hospitalization, starting same day clinical care at the cancer center, and also expediting care for patients with an unclear diagnosis of cancer but with suspected imaging concerns.
Her research interests include access to clinical trials, quality improvement and improving care delivery. In that effort, she has published on work regarding patient reported outcomes (PROs), through distress screening with the Stanford Medicine Cancer Center, and in care for patient with limited English proficiency.
Dr. Roy received her medical degree from Albert Einstein College of Medicine, and then completed residency training at Beth Israel Deaconess Medical Center. She then completed fellowship training in Hematology and Oncology at Stanford, where she was chief fellow. -
Anuja Anand Sathe
Instructor, Medicine - Oncology
Current Research and Scholarly InterestsI am interested in understanding the determinants of therapeutic resistance in cancer. I investigate the composition of the tumor microenvironment and adaptive responses to therapy using single-cell and spatial approaches.
-
Lidia Schapira
Professor of Medicine (Oncology)
BioDr. Schapira is a medical oncologist with clinical expertise in the treatment of breast cancer. As the inaugural Director of Stanford's Cancer Survivorship Program, she has developed a thriving research and clinical program focused on optimizing health outcomes for people living with and beyond cancer. Dr. Schapira is interested in training future generations of physician-scientists as well as the broader community of practicing physicians through the design of innovative educational programs. Dr. Schapira's advocacy for people with cancer led to her appointment as Editor-in-Chief of the American Society of Clinical Oncology's website for the public,Cancer.Net, a position she held from 2015 until-2021. She served on the Board of Directors of the American Psychosocial Oncology Society and as Chair of the Psychosocial Interest Group of the Multinational Society for Supportive Care in Cancer. Dr. Schapira is particularily committed to reducing inequities in cancer outcomes and improve access to cancer care and cancer clinical trials. Dr. Schapira has published numerous manuscripts, lectures both nationally and internationally on issues of cancer survivorship and served as Associate Editor of the narrative section, Art of Oncology, for the Journal of Clinical Oncology from 2013 until 2023.
